Applications of bilateral vascularized femoral bone marrow transplantation for chimerism induction across the major histocompatibility (MHC) barrier: Part II

Annals of Plastic Surgery

Volumn 57, Issue 4, 2006, Pages 422-430

  Klimczak, Aleksandra ^a,c   Agaoglu, Galip ^a   Carnevale, Kevin A ^a,b   Siemionow, Maria ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of Pathology ^*  (United States)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Bilateral vascularized femoral bone transplant; Chimerism induction, TCRmAb CsA protocol

Indexed keywords

CYCLOSPORIN A; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL MIGRATION; CELL VIABILITY; CHIMERA; COMPOSITE GRAFT; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; ISOGRAFT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SURGICAL TECHNIQUE; VASCULARIZED BONE MARROW TRANSPLANT;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; FEMUR; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; MAJOR HISTOCOMPATIBILITY COMPLEX; RATS; RATS, INBRED BN; RATS, INBRED LEW; TRANSPLANTATION CHIMERA;

EID: 33749023872     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sap.0000227049.65952.26     Document Type: Article

References (36)

1. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807-818.
2. Euvrard S, Kanitakis J, Claudy A. Skin cancer after organ transplantation. New Engl J Med. 2003;343:1681-1691.
3. Monaco AP. Prospects and strategies for clinical tolerance. Transplant Proc. 2004;36:227-231.
4. Brent LB. Tolerance and its clinical significance. World J Surg. 2000;24:787-792.
5. Fontes P, Rao AS, Demetris AJ, et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet. 1994;344:151-155.
6. Delis S, Ciancia G, Burke GW, et al. Donor bone marrow transplantation: chimerism and tolerance. Transpl Immunol. 2004;13:105-115.
7. Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of vascularized limb allografts. Plast Reconstr Surg. 1991;87:401-411.
8. Llull R. An open proposal for clinical composite tissue allotransplantation. Transplant Proc. 1998;30:2692-2696.
9. Lukomska B, Durlik M, Cybulska E, et al. Comparative analysis of immunological reconstitution induced by vascularized bone marrow versus bone marrow cell transplantation. Transplant Int. 1996;9(suppl 1):492-496.
10. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation. 2001;71:827-835.
11. Siemionow M, Ulusal BG, Ozmen S, et al. Composite vascularized skin/bone graft model: a viable source for vascularized bone marrow transplantation. Microsurgery. 2004;24:200-206.
12. Siemionow M, Klimczak A, Unal S. Different routes of donor-derived hematopoietic stem cell transplantation for donor-specific chimerism induction across MHC barrier. Transplant Proc. 2005;37:62-64.
13. Lipson RA, Kawano H, Halloran PF, et al. Vascularized limb transplantation in the rat. Transplantation. 1983;35:300-304.
14. Santiago SF, de Faria W, Khan TF, et al. Heterotopic sternum transplant in rats: a new model of avascularized bone marrow transplantation. Microsurgery. 1999;19:330-334.
15. Suzuki H, Patel N, Mathews M, et al. Vascularized bone marrow transplantation: a new surgical approach using isolated femoral bone/bone marrow. J Surg Res. 2000;89:176-183.
16. Tai CY, France MA, Strande LF, et al. An extraperitoneal isolated vascularized bone marrow transplant model in the rat. Transplantation. 2003;75:1591-1593.
17. Ozer K, Oke R, Gurunluoglu R, et al. Induction of tolerance to hind limb allografts in rats receiving cyclosporine A and antilymphocyte serum: effect of duration of the treatment. Transplantation. 2003;75:31-36.
18. Ozer K, Izycki DM, Zielinski M, et al. Development of donor-specific chimerism and tolerance in composite tissue allografts under alphabeta-T-cell receptor monoclonal antibody and cyclosporine a treatment protocols. Microsurgery. 2004;24:248-254.
19. Siemionow M, Izycki DM, Zielinski M. Donor-specific tolerance in fully major histocompatibility complex-mismatched limb allograft transplants under an anti-αβ T-cell receptor monoclonal antibody and cyclosporine A protocol. Transplantation. 2003;76:1662-1668.
20. Agaoglu G, Carnevale KA, Zins JE, et al. Bilateral vascularized femoral bone transplant: a new model of vascularized bone marrow transplantation in rats, part I. Ann Plast Surg. 2006;56:658-664.
21. Petit F, Minns A, Dubernard JM, et al. Composite tissue allotransplantation and reconstructive surgery: first clinical applications. Ann Surg. 2003;237:19-25.
22. Baumeister S, Kleist Ch, Dochler B, et al. Risks of allogeneic hand transplantation. Microsurgery. 2004;24:98-103.
23. Francois CD, Breidenbach WC, Maldonado C, et al. Hand transplantation: comparisons and observations of the first four clinical cases. Microsurgery. 2000;20:360-371.
24. Heidecke CD, Hancock WW, Westerholt S, et al. Alpha/beta-T cell receptor-directed therapy in rat allograft recipients: long-term survival of cardiac allografts after pretreatment with R73 mAb is associated with upregulation of Th2-type cytokines. Transplantation. 1996;61:948-956.
25. Goldshneider I, Gordon LK, Morris RJ. Demonstration of Thy-1 antigen on pluripotent hematopoietic stem cells in the rat. J Exp Med. 1978;148:1351-1366.
26. Hunt SV. The presence of Thy-1 on the surface of rat lymphoid stem cells and colony forming units. Eur J Immunol. 1979;9:853-859.
27. Kroese FGM, De Boer NK, De Boer T, et al. Identification and kinetics of two recently bone marrow-derived B cell population in peripheral lymphoid tissues. Cell Immunol. 1995;162:185-193.
28. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. Lancet. 1992;339:1579-1582.
29. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1003;17:1127-1152.
30. Starzl TE, Demetris AJ, Murase N, et al. The lost chord: microchimerism and allograft survival. Immunol Today. 1996;17:577-584.
31. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med. 1998;339:1905-1913.
32. Starzl TE. Chimerism and tolerance in transplantation. Proc Natl Acad Sci U S A. 2004;101:14607-14614.
33. Tashiro H, Fukuda Y, Hoshino S, et al. Monitoring for engraftment following rat orthotopic liver transplantation by in vitro amplification of Y-chromosome gene using polymerase chain reaction. Cell Transplant 1995;4(suppl 1):S61-S63.
34. Talmor M, Steinman RM, Codner MA, et al. Bone marrow-derived chimerism in non-irradiated, cyclosporine-treated rats receiving microvascularized limb transplants: evidence for donor-derived dendritic cells in recipient lymphoid tissues. Immunology. 1995;86:448-455.
35. Siemionow M, Izycki D, Ozer K, et al. Role of thymus in operational tolerance induction in limb allograft transplant model. Transplantation. 2006;81:15.
36. Muramatsu K, Bishop AT. Cell repopulation in vascularized bone grafts. J Orthop Res. 2002;20:772-778.